Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Safety of secukinumab for the treatment of active ankylosing spondylitis

(2021) Javier Loricera et al.   Expert Opinion On Drug Safety

Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis

(2021) Yinzhu Jin et al.   ARTHRITIS CARE & RESEARCH

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

(2021) Ulf Lindström et al.   ANNALS OF THE RHEUMATIC DISEASES

Infective dermatitis after treatment with secukinumab

(2021) T. O. Utiyama et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

(2021) Annamaria Mascolo et al.   DRUG SAFETY

Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies

(2020) M. Augustin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

(2020) April W. Armstrong et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system

(2020) Yingying Hu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach

(2020) T Tsakok et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab: A Review in Ankylosing Spondylitis

(2019) Hannah A. Blair   DRUGS

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

(2019) Stefan Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

The IL-17 Family of Cytokines in Health and Disease

(2019) Mandy J. McGeachy et al.   IMMUNITY

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

(2019) Fan Bai et al.   Journal of Immunology Research

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

(2019) Elsie Grace et al.   Dermatology and Therapy

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

(2018) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab

(2018) María José Fobelo Lozano et al.   Journal of Crohns & Colitis

Atopic-like dermatitis after Secukinumab injection: a case report

(2018) Martina Burlando et al.   Dermatologic Therapy

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

(2018) Jürgen Braun et al.   RHEUMATOLOGY

Old and New Biological Therapies for Psoriasis

(2017) Kirsten Rønholt et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

(2017) Jillian Frieder et al.   Therapeutic Advances in Chronic Disease

Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis

(2016) Ju Yeon Ryoo et al.   ANNALS OF PHARMACOTHERAPY

A systematic review of worldwide epidemiology of psoriasis

(2016) I.M. Michalek et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

An overview of developing TNF-α targeted therapy for the treatment of psoriasis

(2015) Molly Campa et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Interleukin-17 inhibition in psoriatic arthritis

(2015) Philip Helliwell et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective TNF-α inhibitor-induced injection site reactions

(2013) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

IL-17 targeted therapies for psoriasis

(2013) Andrea Chiricozzi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Specific targeting of interleukin-23p19 as effective treatment for psoriasis

(2013) Adriane A. Levin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens

(2011) Xinyang Song et al.   NATURE IMMUNOLOGY

Mutual Antagonism of T Cells Causing Psoriasis and Atopic Eczema

(2011) Stefanie Eyerich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A protective function for interleukin 17A in T cell–mediated intestinal inflammation

(2009) William O'Connor Jr et al.   NATURE IMMUNOLOGY